Cytokinetics, Inc.
Cytokinetics, Incorporated Announces Results of Annual Meeting of Stockholders
Summary
Cytokinetics, Incorporated reported the outcomes of its Annual Meeting of Stockholders held on May 14, 2025. The company's shareholders elected John T. Henderson, B. Lynne Parshall, and Muna Bhanji as Class III Directors. Additionally, shareholders approved amendments to the Amended and Restated 2004 Equity Incentive Plan, increasing the number of authorized shares by 5,000,000, and to the Amended and Restated Certificate of Incorporation, increasing the number of authorized shares of common stock from 163,000,000 to 326,000,000. Shareholders also ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved, on an advisory basis, the compensation of the named executive officers.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement